BRISTOL MYERS SQUIBB CO BMY

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger.

We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry. Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology, hematology, immunology, cardiovascular, neuroscience and other areas where we can also create long-term value. Our priorities are to focus on transformational medicines where we have a competitive advantage, drive operational excellence throughout the organization and strategically allocate capital for long-term growth and shareholder returns. We are driving commercial execution in our key first-in-class and/or best-in-class marketed products, where we continue to expand and see potential for further expansion into the future. For a further discussion of our strategy initiatives, refer to "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations—Strategy."

Last close 61.48 2026-10-23
Market cap $125.59B 2026-06-30 share count
52-week range 42.52 - 68.64

Valuation FY2025 figures against the last close

P/S2.6x
P/E17.8x
P/FCF9.8x
EV/EBITDA—
Dividend yield4.0%
Diluted EPS3.46

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • International
  • Other
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 33.3B (69.1%) 69% United States International, FY2025: 13.8B (28.7%) 29% International Other, FY2025: 1.1B (2.3%) FY2024 United States, FY2024: 34.1B (70.6%) 71% International, FY2024: 13.2B (27.3%) 27% Other, FY2024: 996M (2.1%) FY2023 United States, FY2023: 31.2B (69.3%) 69% International, FY2023: 13.1B (29.1%) 29% Other, FY2023: 699M (1.6%)
Region FY2025FY2024FY2023
United States $33.28B $34.10B $31.21B
International $13.83B $13.20B $13.10B
Other $1.09B $996.0M $699.0M

As the company reported it, from the “REVENUE - Disaggregation of Revenue by Product and Region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $48.19B$48.30B$45.01B$46.16B$46.38B$42.52B$26.14B$22.56B$20.78B$19.43B
Cost of revenue $13.94B$13.97B$10.69B$10.14B$9.94B$11.77B$8.08B$6.47B$6.01B$4.97B
Gross profit $34.26B$34.33B$34.31B$36.02B$36.45B$30.75B$18.07B$16.09B$14.68B$14.48B
R&D $9.95B$11.16B$9.30B$9.51B$10.20B$10.05B$6.15B$6.33B$6.47B$5.01B
SG&A $7.27B$8.41B$7.77B$7.81B$7.69B$7.66B$4.87B$4.55B$4.75B$4.98B
Total operating expenses $38.87B$56.68B$36.57B$38.45B$38.29B$49.39B$21.17B$16.59B$15.64B$13.51B
Interest expense $1.89B$1.95B$1.17B$1.23B$1.33B$1.42B$656.0M$183.0M$196.0M$167.0M
Pre-tax income $9.33B-$8.38B$8.44B$7.71B$8.10B-$6.87B$4.97B$5.97B$5.13B$5.92B
Income tax $2.27B$554.0M$400.0M$1.37B$1.08B$2.12B$1.51B$1.02B$4.16B$1.41B
Net income $7.05B-$8.95B$8.03B$6.33B$6.99B-$9.02B$3.44B$4.92B$1.01B$4.46B
EPS, basic 3.47-4.413.882.973.15-3.992.023.010.612.67
EPS, diluted 3.46-4.413.862.953.12-3.992.013.010.612.65
Shares, diluted (wtd. avg.) 2.04B2.03B2.08B2.15B2.25B2.26B1.71B1.64B1.65B1.68B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $10.21B$10.35B$11.52B$9.32B$14.32B$14.97B$12.82B$6.91B$5.42B$4.24B
Short-term investments $464.0M$513.0M$816.0M$130.0M$2.99B$1.28B$3.05B$1.85B$1.39B$2.11B
Receivables $9.59B$9.01B$8.88B$8.15B$7.98B$7.22B$6.48B$4.64B$4.35B$3.77B
Inventory $2.69B$2.56B$2.66B$2.34B$2.10B$2.07B$4.29B$1.20B$1.17B$1.24B
Total current assets $29.39B$29.78B$31.77B$27.27B$33.26B$30.19B$29.35B$17.72B$14.85B$13.70B
Property, plant and equipment $7.54B$7.14B$6.65B$6.25B$6.05B$5.89B$6.25B$5.03B$5.00B$4.98B
Goodwill $21.75B$21.72B$21.17B$21.15B$20.50B$20.55B$22.49B$6.54B$6.86B$6.88B
Other intangibles $19.10B$23.31B$27.07B$35.86B$42.53B$53.24B$63.97B$1.09B$1.21B$1.39B
Total assets $90.04B$92.60B$95.16B$96.82B$109.31B$118.48B$55.16B$34.83B$33.08B$32.94B
Accounts payable $3.58B$3.60B$3.26B$3.04B$2.95B$2.71B$2.44B$1.89B$2.25B$1.66B
Short-term debt $1.98B$1.83B$2.87B$3.90B$4.76B$2.00B$2.76B$1.25B$0$749.0M
Total current liabilities $23.42B$23.77B$22.26B$21.89B$21.87B$19.08B$18.30B$10.65B$9.56B$8.84B
Long-term debt $42.85B$47.60B$36.65B$35.06B$39.60B$48.34B$43.39B$5.63B$5.78B$7.24B
Total liabilities $71.53B$76.22B$65.67B$65.70B$73.31B$80.60B$78.25B$20.86B$21.70B$17.36B
Retained earnings $16.90B$14.91B$28.77B$25.50B$23.82B$21.28B$34.47B$34.06B$31.16B$33.51B
Total equity $18.47B$16.34B$29.43B$31.06B$35.95B$37.82B$51.60B$15.32B$12.91B$14.54B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $14.16B$15.19B$13.86B$13.07B$16.21B$14.05B$8.21B$7.07B$5.28B$3.06B
Depreciation and amortisation $4.01B$9.60B$9.76B$10.28B$10.69B$10.38B$1.75B$637.0M$789.0M$382.0M
Stock-based compensation $553.0M$507.0M$518.0M$457.0M$583.0M$779.0M$441.0M$221.0M$199.0M$205.0M
Capital expenditure $1.31B$1.25B$1.21B$1.12B$973.0M$753.0M$836.0M$951.0M$1.05B$1.22B
Investing cash flow -$4.13B-$21.35B-$2.29B-$1.06B-$538.0M-$10.86B-$9.91B-$2.00B-$66.0M$1.48B
Financing cash flow -$10.35B$5.13B-$9.42B-$16.96B-$16.22B-$1.15B$7.62B-$3.54B-$4.08B-$2.65B
Dividends paid $5.04B$4.86B$4.74B$4.63B$4.40B$4.08B$2.68B$2.61B$2.58B$2.55B
Buybacks $0$0$5.16B$8.00B$6.29B$1.55B$7.30B$320.0M$2.47B$231.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000014272-26-000004.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -20B 0 20B 40B 60B Revenue, FY2016: 19.4B Gross profit, FY2016: 14.5B Net income, FY2016: 4.5B Revenue, FY2017: 20.8B Gross profit, FY2017: 14.7B Net income, FY2017: 1B Revenue, FY2018: 22.6B Gross profit, FY2018: 16.1B Net income, FY2018: 4.9B Revenue, FY2019: 26.1B Gross profit, FY2019: 18.1B Net income, FY2019: 3.4B Revenue, FY2020: 42.5B Gross profit, FY2020: 30.7B Net income, FY2020: -9B Revenue, FY2021: 46.4B Gross profit, FY2021: 36.4B Net income, FY2021: 7B Revenue, FY2022: 46.2B Gross profit, FY2022: 36B Net income, FY2022: 6.3B Revenue, FY2023: 45B Gross profit, FY2023: 34.3B Net income, FY2023: 8B Revenue, FY2024: 48.3B Gross profit, FY2024: 34.3B Net income, FY2024: -8.9B Revenue, FY2025: 48.2B Gross profit, FY2025: 34.3B Net income, FY2025: 7.1B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $19.43B $20.78B $22.56B $26.14B $42.52B $46.38B $46.16B $45.01B $48.30B $48.19B
Gross profit $14.48B $14.68B $16.09B $18.07B $30.75B $36.45B $36.02B $34.31B $34.33B $34.26B
Net income $4.46B $1.01B $4.92B $3.44B -$9.02B $6.99B $6.33B $8.03B -$8.95B $7.05B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
REGN REGENERON PHARMACEUTICALS, INC. $82.76B 19.4x 1.0%